Shanghai Pharmaceutical Group Co., Ltd., referred to as Shanghai Pharmaceutical for short, is the major shareholder of Shanghai Pharmaceutical (Group) Co., Ltd., with the shareholding ratio of 65,438+09.3732%, and the actual controller is Shanghai SASAC.
Since its establishment, Shanghai Pharmaceutical has continuously increased its investment in R&D and introduced new products, laying a solid foundation for the company's future development. In 2022, the company's R&D investment in the first half of the year reached 2,366,543.8 million yuan, a year-on-year increase of 28.66%, and it also won many honors and awards at home and abroad, with a high level and strength in pharmaceutical research and development.
At present, Shanghai Pharmaceutical has been ranked in the Fortune Global 500 list for many times, and ranked 465th in the Fortune Global 500 in 2022, up 1 1 bit over the previous year.
If you need to know more about Shanghai Pharmaceutical Group Co., Ltd., I suggest you go to the enterprise to find out-check the enterprise for free.